HER2-Directed ADCs in Gastric Cancer Several antibody-drug conjugates (ADCs) have recently received approval for use in treating a range of solid cancers. This poses difficulties when handling a variety of adverse treatment-related events, some of which can take practitioners into uncharted area. After viewing this CME activity, medical oncologists, pulmonologists, urologists, pathologists, oncology NPs, PAs, oncology nurses, oncology pharmacists, and other HCPs caring for patients with solid tumors should be able to describe the elements of an antibody-drug conjugate (ADC) that may cause adverse events (AEs), identify AEs that result in treatment interruption or discontinuation, and suggest a strategy for managing the key AEs.

Patients with newly diagnosed acute myeloid leukemia (AML) have had better results thanks to alterations to cytarabine/anthracycline-based intense chemotherapy, including the addition of high-dose cytarabine and adjustments to the dosage schedule or type of anthracycline.

It may not come as a surprise that there are so many doctors running for politics given that healthcare is a major legislative priority. According to the Patients Action Network of the American Medical Association, 19 doctors are currently serving in the 118th Congress. The task ahead for these 19 congressional representatives will be challenging. The AMA is concentrated on stopping Medicare payment cuts and implementing prior authorization reform among the myriad healthcare concerns facing the nation.

Healthgrades communicates performance in two ways—through ratings and awards—to assist consumers in evaluating and comparing hospital performance specific to specialist service lines and speciality emphasis areas. Using Medicare inpatient data from the Medicare Provider Analysis and Review (MedPAR) file purchased from the Centers for Medicare and Medicaid Services (CMS) for the years 2019 through 2021, hospitals were evaluated for overall clinical excellence and measure performance. Data on patient outcomes for 31 diseases or treatments were examined for almost all hospitals in the nation. Also, with the fewest occurrences of 14 avoidable patient safety events, hospitals in the top 10% of the country are honored with the Patient Safety Excellence Award, and analyzing data from surveys of the hospital’s own patients to evaluate patient experience across 10 metrics, the top 15% of hospitals receive the Outstanding Patient Experience Award. Finally, each year, Healthgrades recognizes hospitals in the United States that offer the most common gynecologic treatments and where patients are at a decreased risk of complications during their stay for labor and delivery.

A compilation of each lymph node level’s radiologically practical bounds, which include: Submental and submandibular at Level I Level II: Deep cervical (internal jugular) chain Level III: deep cervical (internal jugular) chain Lower internal jugular (deep cervical) chain, level IV Posterior triangle at level V Central (anterior) compartment at level VI

In conclusion, daratumumab (Darzalex) (D) was added to lenalidomide, bortezomib, and dexamethasone (RVd) in NDMM patients who were transplant-eligible, and this led to enhanced stringent complete response (sCR) and minimal residual disease (MRD)-negative rates, a tolerable safety profile, and no clinically meaningful effects on stem cell mobilization or engraftment. These findings suggest that the D-RVd combination may become a new standard of care for NDMM who are transplant-eligible.